Literature DB >> 2914482

Survival time of patients with pleural metastatic carcinoma predicted by glucose and pH studies.

F Rodriguez-Panadero1, J Lopez-Mejias.   

Abstract

STUDY
OBJECTIVE: To determine the survival time of patients with pleural metastatic carcinoma diagnosed by thoracoscopy, as related to the pleural glucose and pH levels, and to the extension of pleural neoplastic lesions.
DESIGN: Cohort analytic prospective study. Follow-up of the patients from diagnostic thoracoscopy to death (range: one to 29 months).
SETTING: Referral Pneumology Service at a Tertiary Care Center. PATIENTS: Consecutive sample of 50 patients with pleural metastatic carcinoma diagnosed by thoracoscopy. Three patients were lost in the follow-up.
INTERVENTIONS: Talc pleurodesis was performed after diagnosis and with the same technique in every case. MEASUREMENTS AND
RESULTS: In all the cases, the extension of the tumorous lesions was determined by thoracoscopy (classified on a scale from 0 to 9) and the survival time was studied from the time that thoracoscopic diagnosis was made. On the same or the previous day as the exploration, blood and pleural fluid glucose levels as well as arterial and pleural pH and gas tensions were determined.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2914482     DOI: 10.1378/chest.95.2.320

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  13 in total

1.  Pleural fluid findings as prognostic factors for malignant pleural mesothelioma.

Authors:  Tanseli Efeoglu Gonlugur; Ugur Gonlugur
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

2.  Examination of the thoracic cavity and lung lobectomy by means of thoracoscopy in dogs.

Authors:  F García; D Prandi; T Peña; J Franch; O Trasserra; J de la Fuente
Journal:  Can Vet J       Date:  1998-05       Impact factor: 1.008

Review 3.  Diagnostic tests in pleural effusion--an update.

Authors:  N Berkman; M R Kramer
Journal:  Postgrad Med J       Date:  1993-01       Impact factor: 2.401

4.  Pleural Fluid Adenosine Deaminase (ADA) Predicts Survival in Patients with Malignant Pleural Effusion.

Authors:  Ricardo Mingarini Terra; Leila Antonangelo; Alessandro Wasum Mariani; Ricardo Lopes Moraes de Oliveira; Lisete Ribeiro Teixeira; Paulo Manuel Pego-Fernandes
Journal:  Lung       Date:  2016-06-14       Impact factor: 2.584

5.  Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases.

Authors:  Nikolaos Barbetakis; Christos Asteriou; Fani Papadopoulou; Georgios Samanidis; Dimitrios Paliouras; Athanassios Kleontas; Konstantina Lyriti; Ioannis Katsikas; Christodoulos Tsilikas
Journal:  J Cardiothorac Surg       Date:  2010-04-19       Impact factor: 1.637

6.  Long-term outcome of pleurodesis with OK-432 in metastatic breast cancer: a new risk model for success from an analysis of 75 cases.

Authors:  Nobuaki Matsubara; Kuniaki Itoh; Hirofumi Mukai; Shunji Nagai
Journal:  Int J Clin Oncol       Date:  2011-10-07       Impact factor: 3.402

Review 7.  Malignant pleural effusions: appropriate treatment approaches.

Authors:  Yener Aydin; Atila Turkyilmaz; Yavuz Selim Intepe; Atilla Eroglu
Journal:  Eurasian J Med       Date:  2009-12

Review 8.  Management of malignant pleural effusion.

Authors:  Jack A Kastelik
Journal:  Lung       Date:  2013-01-13       Impact factor: 2.584

Review 9.  The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors:  Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

10.  Relationship of pleural fluid pH and glucose: a multi-centre study of 2,971 cases.

Authors:  Deirdre B Fitzgerald; Su Lyn Leong; Charley A Budgeon; Kevin Murray; Andrew Rosenstengal; Nicola A Smith; Silvia Bielsa; Amelia O Clive; Nick A Maskell; José M Porcel; Y C Gary Lee
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.